- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.08. | Almirall and Absci expand AI dermatological drug discovery partnership | ||
| 26.08. | UK government publishes 10-Year Health Plan for England to 'reinvent' NHS | ||
| 22.08. | Boehringer's Hernexeos granted FDA accelerated approval for lung cancer patients | ||
| 22.08. | FDA approves Celltrion's Actemra biosimilar Avtozma for cytokine release syndrome | ||
| 22.08. | Why life cycle management is pharma's most underrated capability | ||
| 21.08. | DEBRA and Queen Mary partner to advance epidermolysis bullosa drug development | ||
| 21.08. | The delicate balancing act of incorporating technology into healthcare | ||
| 21.08. | NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine | ||
| 21.08. | From spark to surge: rethinking partnerships in healthcare communications | ||
| 20.08. | AbbVie/Genmab's lymphoma drug shows promise in phase 3 combination trial | ||
| 20.08. | FDA approves Jazz Pharmaceuticals' Modeyso as first drug for ultra-rare brain cancer | ||
| 20.08. | Empathy is not a soft skill - it's a strategic one | ||
| 19.08. | Sanofi's multiple myeloma candidate granted FDA orphan drug designation | ||
| 19.08. | Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis | ||
| 19.08. | Are botanical drugs part of the future of medicine? | ||
| 18.08. | Gilead Sciences' Biktarvy granted FDA approval for expanded HIV use | ||
| 18.08. | FDA approves Apellis' Empaveli for two rare kidney diseases | ||
| 18.08. | Trust and trends - proactive protection | ||
| 15.08. | Eli Lilly's Alzheimer's drug Kisunla shows growing benefit in long-term study | ||
| 15.08. | BMS granted FDA priority review for Breyanzi in marginal zone lymphoma | ||
| 15.08. | Improving transparency and traceability within the supply chain's first mile | ||
| 14.08. | Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours | ||
| 14.08. | FDA approves PTC Therapeutics' Sephience to treat rare metabolic disorder PKU | ||
| 14.08. | Motivating low-performance teams | ||
| 13.08. | GSK and Hengrui enter multi-programme collaboration agreement worth $12bn |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .